Pharmaron Beijing : LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS OF THE SECOND SESSION OF THE BOARD
July 28, 2020 at 06:15 am EDT
Share
Pharmaron Beijing Co., Ltd.*
康龍化成(北京)新藥技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3759)
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS OF
THE SECOND SESSION OF THE BOARD
The members of the second session of the board of directors (the "Board") of Pharmaron Beijing Co., Ltd. (the "Company") are set out below:
Executive Directors
Dr. LOU Boliang (chairman of the Board)
Mr. LOU Xiaoqiang
Ms. ZHENG Bei
Non-executive Directors
Mr. CHEN Pingjin
Mr. HU Baifeng
Mr. LI Jiaqing
Mr. ZHOU Hongbin
Independent non-executive Directors
Mr. DAI Lixin
Ms. CHEN Guoqin
Mr. TSANG Kwan Hung Benson
Mr. YU Jian
1
BOARD COMMITTEES UNDER THE SECOND SESSION OF THE BOARD
There are four Board committees under the second session of the Board. The composition of the Board committees is set out in the table below:
Committee
Audit
Remuneration
Nomination
Strategy
and Appraisal
Director
Committee
Committee
Committee
Committee
Dr. LOU Boliang
-
M
M
C
Mr. LOU Xiaoqiang
-
M
-
M
Ms. ZHENG Bei
-
-
M
-
Mr. CHEN Pingjin
-
-
-
M
Mr. HU Baifeng
-
-
-
-
Mr. LI Jiaqing
-
-
-
M
Mr. ZHOU Hongbin
-
-
-
-
Mr. DAI Lixin
-
-
-
M
Ms. CHEN Guoqin
M
C
C
-
Mr. TSANG Kwan Hung Benson
M
M
M
-
Mr. YU Jian
C
M
M
-
Notes:
Chairperson of the relevant Board committees M Member of the relevant Board committees
Beijing, the PRC
July 28, 2020
For identification purposes only
2
Attachments
Original document
Permalink
Disclaimer
Pharmaron Beijing Co. Ltd. published this content on 28 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2020 10:15:04 UTC
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).